Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor

Acta Oncologica

Volumn 42, Issue 1, 2003, Pages 62-70

  Kanda, Akio ^a   Ebihara, Satoru ^a   Takahashi, Hidenori ^a   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DRUG INFUSION; PLASMA DIAGNOSTICS; RNA;

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID);

TUMORS;

LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; JAPAN; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR VOLUME; UMBILICAL VEIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; LYMPHOKINES; MICE; PHENYLPROPIONATES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037223801     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/0891060310002258     Document Type: Article

References (27)

1. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-64.
2. Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997; 74: 64-8.
3. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-4.
4. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1987; 272: 634-6.
5. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
6. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
7. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
8. Williams CS, Tsujii M, Reese J, Dey SK, Dubois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-94.
9. Matsuda K, Tanaka Y, Ushiyama S, Ohnishi K, Yamazaki M. Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl) phenyl] propionate dihydrate (CS-600), a new anti-inflammatory drug, and its active metabolite in vitro and in vivo. Biochem Pharmacol 1984; 33: 2473-8.
10. Sugimoto M, Kojima T, Asami M, Iizuka Y, Matsuda K. Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug. Biochem Pharmacol 1991; 42: 2363-8.
11. Waikakul S, Waikakul W. A post marketing survey on the side-effects of loxoprofen. J Medical Ass Thailand 1999; 82: 721-6.
12. Zhang L, Conejo-Garcia JR, Yang N, et al. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun 2002; 292: 860-8.
13. Bhatt AJ, Amin SB, Chess PR, Watkins RH, Maniscalco WM. Expression of vascular endothelial growth factor and FIk-1 in developing and glucocorticoid-treated mouse lung. Pediatr Res 2000; 47: 606-13.
14. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998; 95: 15809-14.
15. Shima DT, Kuroki M, Deutch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. J Biol Chem 1996; 271: 3877-83.
16. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
17. Imaizumi T, Itaya H, Nasu S, et al. Expression of vascular endothelial growth factor in human umbilical vein endothelial cells stimulated with interleukin-1α. Thromb Haemost 2000; 83: 949-55.
18. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3: 177-82.
19. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177: 57-63.
20. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6: 2006-11.
21. Park JE, Keller GA, Ferrara N. Vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-26.
22. 1 in osteoblasts. J Clin Invest 1994; 93: 2490-6.
23. Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res 1998; 47(Suppl 2): S102-6.
24. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001-5.
25. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396: 77-80.
26. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-45.
27. Kanda A, Yanai M, Hirai H, Suzuki T, Sasaki H. Chemotherapy for older people with non-small cell lung cancer. J Am Geriatr Soc 2000; 48: 1536-7.